Table 3.

Comparison of Viremia Among Patients, by Treatment Duration and Clinical/Immunological Characteristics

	Detectable VL (> 1000 Copies/mL)
Characteristic	ART Naive (Late Presentersa)	ART <6 mo (Late Presentersa)	ART >6 mo (ART Experienced)
Kenyab
WHO stage 3 or 4c	NA	NA	33 (64.7)
CD4 count <100 cells/μL	NA	NA	31 (83.8)d
DRC
WHO stage 3 or 4c	46 (90.2)	22 (37.3)	105 (63.5)
CD4 count <100 cells/μL	35 (92.1)	13 (43.3)	67 (80.7)

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: ART, antiretroviral therapy; DRC, Democratic Republic of Congo; NA, not applicable; VL, viral load; WHO, World Health Organization.

^aART-naive late presenters include both those who had and had not been previously diagnosed.

^bViral load done only during the last month of the study and only on patients on ART >6 months.

^cDefined as WHO stage 3/4 illness at admission to inpatient care.

^dImmunological failures.